MAPT and myotonic dystrophy type 1: Next to some clinical studies that hint at a neurodegenerative cognitive decline in DM1 patients [16], explorations of cerebrospinal fluid detected increased levels of phosphorylated tau proteins, however, with an unclear clinical relevance [24, 36].